Bavarian Nordic A/S (CPH:BAVA), a fully integrated biotechnology company, announced on Wednesday that the first patient has been dosed in a phase 2 study evaluating the combination therapy of its cancer vaccine, CV301, and Bristol Myers Squibb's checkpoint inhibitor, nivolumab (OPDIVO), for the treatment of patients with resectable hepatic-limited metastatic colorectal cancer (mCRC).
Reportedly, Bavarian Nordic's CV301 is designed to create a T-cell response against the tumour antigens CEA and MUC1, which are overexpressed on multiple solid tumours, including colorectal cancers. Preclinical data supports the premise that CV301 is highly synergistic with checkpoint inhibitors and holds the potential to broaden their efficacy in cancers where monotherapy has been ineffective.
This randomised, multiple-site, phase 2 trial is being led by Darren Carpizo, M.D., Ph.D, the director of the Liver Cancer and Bile Duct Cancer Programme at Rutgers Cancer Institute, with material support from Bavarian Nordic and Bristol Myers Squibb.
This study is expected to enrol 78 patients. Prior to surgical removal of their tumours, patients will be randomised to receive four cycles of either chemotherapy plus nivolumab or a combination of chemotherapy, nivolumab, and CV301. After resection, patients will continue receiving respective treatments in each study arm. Overall survival (OS) and several secondary measures will be evaluated in each arm.
CV301 is an immunotherapy candidate which is being developed under a CRADA with the National Cancer Institute (NCI). CV301 targets two tumour-associated antigens, CEA and MUC1, which are over-expressed in multiple solid tumours, including lung, bladder, colorectal and pancreatic cancers.
Bavarian Nordic is focused on the development of innovative and safe therapies against cancer and infectious diseases.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer